Skip to Content
scroll

Imugene (IMU)

ASX.IMU $0.20

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

ASX.IMU $0.20

20 MINUTE DELAYED

TODAY

8.33 %

1 YEAR RETURN

0.00%

VOLUME

20,200,371

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.13

0.63

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

0.20

Change

0.02 (8.33)

Bid / Ask

0.20 - 0.20

Volume

20,200,371

Volume (3mths avg)

0

Turnover

3,946,789

Open

0.19

Day Range

0.18 - 0.21

VWAP

0.20

Prev Close

0.18

Last Trade

06.10 01/07 (AEST)

i

KEY INFORMATION
Sector

Healthcare

Shares Issued

4,885,986,365

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

Dividend Pay Date

29 MAR 2006

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

Yield %

0.00

Market Cap

0.00

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
OPINION
ACTION
image description

Business Summary

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
image description

Relevant suggested news and content from the site

Back to top